Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rhonda Baldone

MOHS-Micrographic Surgery Covington, LA Medical Doctor

NPI 1245298876 CMS profile 55936

150 Lakeview Circle, Covington, LA 70433

Open in the dashboard

General payments

$71,899

451 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$146,365 paid to institutions, not to them · program years 2021–2024

Through program year 2025, Rhonda Baldone of Covington, LA is reported in the CMS Open Payments database as having received $71,899 across 451 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $146,365 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,127 54
2024 General $1,430 63
2023 General $5,886 55
2022 General $24,230 82
2021 General $15,598 67
2020 General $7,336 34
2019 General $16,292 96

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rhonda Baldone
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Rhonda Baldone were reported at $1,127. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Rhonda Baldone MOHS-Micrographic Surgery median Middle half National median
2019 $16,292 $316 $106–$785 $163
2020 $7,336 $162 $68–$412 $114
2021 $15,598 $243 $87–$654 $132
2022 $24,230 $300 $102–$887 $149
2023 $5,886 $364 $125–$1,010 $160
2024 $1,430 $445 $142–$1,108 $164
2025 $1,127 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Galderma Laboratories, L.P. $63,923 100 payments
  2. AbbVie, Inc. $1,185 68 payments
  3. UCB, Inc. $822 30 payments
  4. LEO Pharma Inc. $708 26 payments
  5. Merz North America, Inc. $627 10 payments
  6. Genzyme Corporation $602 30 payments
  7. Pfizer Inc. $560 29 payments
  8. Janssen Biotech, Inc. $384 14 payments
  9. Sun Pharmaceutical Industries Inc. $365 14 payments
  10. Allergan Inc. $349 19 payments
  11. Other $2,373 111 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $57,390 16 payments
  2. Food and Beverage $9,920 403 payments
  3. Travel and Lodging $4,425 30 payments
  4. Education $163 2 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT $679 34 payments
  2. Cimzia $511 20 payments
  3. ADBRY $510 14 payments
  4. EUCRISA $444 24 payments
  5. SKYRIZI $430 29 payments
  6. RINVOQ $418 23 payments
  7. Xeomin $403 8 payments
  8. CIBINQO $335 18 payments
  9. Bimzelx $312 10 payments
  10. TREMFYA $308 10 payments
  11. Other $4,556 227 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

502

Median for Dermatology: 534

Drug cost

$9,036

Median for Dermatology: $67,151

Branded share of claims

7.8%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clobetasol Propionate Generic 61 $2,124
Metronidazole Generic 22 $962
Doxycycline Hyclate Generic 41 $854
Finasteride Generic 66 $840
Valacyclovir Valacyclovir Hcl Brand 39 $814
Desonide Generic 19 $696
Triamcinolone Acetonide Generic 61 $612
Ketoconazole Generic 43 $600
Spironolactone Generic 14 $461
Doxycycline Monohydrate Generic 19 $276

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 81 billing codes

Paid by Medicare

$144,758

Of which drugs: $6,239

Medicare patients

525

Average age 75

Services billed

3,642

312 women, 213 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 44%
Ischemic heart disease 35%
Diabetes 20%
Chronic kidney disease 20%
Atrial fibrillation 18%
Cancer 15%
Depression 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 15 20 $6,087
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 34 78 $55

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Bimzelx
  • UCB, Inc. $233
$233 — —
DUPIXENT
  • GENZYME CORPORATION $140
  • Regeneron Healthcare Solutions, Inc. $80
$220 — —
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $142
$142 — —
SKYRIZI
  • AbbVie, Inc. $90
$90 — —
RINVOQ
  • AbbVie, Inc. $84
$84 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

451 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record